Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$3.87 -7.0%	$4.24	$3.87 ▼ $9.16	$270.17M	1.55	367,941 shs	571,996 shs
CPHI China Pharma	$1.52 -17.8%	$0.96	$0.38 ▼ $19.19	$74.97M	1.14	1.98 million shs	3.50 million shs
INDP Indaptus Therapeutics	$2.61 -5.8%	$2.67	$0.92 ▼ $10.57	$295.56M	1.11	75,431 shs	55,164 shs
UTZ Utz Brands	$14.10 +0.0%	$7.97	$6.78 ▼ $14.44	$2.03B	0.82	6.23 million shs	3.98 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	-6.97%	-8.08%	-2.27%	-20.04%	-55.57%
CPHI China Pharma	-17.84%	+38.18%	+137.50%	+156.76%	-16.25%
INDP Indaptus Therapeutics	-5.78%	+3.16%	-26.48%	-20.91%	-75.05%
UTZ Utz Brands	+0.07%	+94.82%	+91.90%	+81.10%	-2.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$3.87 -7.0%	$4.24	$3.87 ▼ $9.16	$270.17M	1.55	367,941 shs	571,996 shs
CPHI China Pharma	$1.52 -17.8%	$0.96	$0.38 ▼ $19.19	$74.97M	1.14	1.98 million shs	3.50 million shs
INDP Indaptus Therapeutics	$2.61 -5.8%	$2.67	$0.92 ▼ $10.57	$295.56M	1.11	75,431 shs	55,164 shs
UTZ Utz Brands	$14.10 +0.0%	$7.97	$6.78 ▼ $14.44	$2.03B	0.82	6.23 million shs	3.98 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	-6.97%	-8.08%	-2.27%	-20.04%	-55.57%
CPHI China Pharma	-17.84%	+38.18%	+137.50%	+156.76%	-16.25%
INDP Indaptus Therapeutics	-5.78%	+3.16%	-26.48%	-20.91%	-75.05%
UTZ Utz Brands	+0.07%	+94.82%	+91.90%	+81.10%	-2.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.44	Hold	$14.00	261.76% Upside
CPHI China Pharma	0.00	N/A	N/A	N/A
INDP Indaptus Therapeutics	1.00	Sell	N/A	N/A
UTZ Utz Brands	2.09	Hold	$13.39	-5.03% Downside

Current Analyst Ratings Breakdown

Latest CPHI, UTZ, INDP, and BCYC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2026	UTZ Utz Brands	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$10.00 ➝ $14.25
7/22/2026	UTZ Utz Brands	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$14.25
7/22/2026	UTZ Utz Brands	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$15.00 ➝ $14.25
7/22/2026	UTZ Utz Brands	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2026	UTZ Utz Brands	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$15.00 ➝ $14.25
7/21/2026	UTZ Utz Brands	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$14.25
7/21/2026	UTZ Utz Brands	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$14.25
7/21/2026	UTZ Utz Brands	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$14.00
7/21/2026	UTZ Utz Brands	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight
7/17/2026	INDP Indaptus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/16/2026	UTZ Utz Brands	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$8.50 ➝ $8.00

(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$72.86M	3.71	N/A	N/A	$8.79 per share	0.44
CPHI China Pharma	$3.99M	15.43	N/A	N/A	$0.70 per share	2.17
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	$1.40 per share	N/A
UTZ Utz Brands	$1.44B	1.41	$1.41 per share	10.03	$9.41 per share	1.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$218.96M	-$3.15	N/A	N/A	N/A	-344.95%	-35.74%	-29.54%	8/7/2026 (Estimated)
CPHI China Pharma	-$3.08M	-$0.55	N/A	N/A	N/A	-85.56%	-63.93%	-31.42%	N/A
INDP Indaptus Therapeutics	-$20.85M	-$15.40	N/A	N/A	N/A	N/A	-1,030.07%	-299.69%	8/17/2026 (Estimated)
UTZ Utz Brands	$800K	-$0.10	17.41	16.78	5.12	-0.58%	8.61%	4.17%	8/5/2026 (Estimated)

Latest CPHI, UTZ, INDP, and BCYC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q2 2026	INDP Indaptus Therapeutics	-$1.57	N/A	N/A	N/A	N/A	N/A
8/7/2026	Q2 2026	BCYC Bicycle Therapeutics	-$0.5640	N/A	N/A	N/A	$4.22 million	N/A
8/5/2026	Q2 2026	UTZ Utz Brands	$0.19	N/A	N/A	N/A	$374.18 million	N/A
5/15/2026	Q1 2026	INDP Indaptus Therapeutics	-$1.87	-$0.23	+$1.64	-$0.23	N/A	N/A
5/6/2026	Q1 2026 Prepared remarks	UTZ Utz Brands	$0.14	$0.15	+$0.01	-$0.02	$361.77 million	$361.30 million
4/30/2026	Q1 2026	BCYC Bicycle Therapeutics	-$0.6209	-$0.87	-$0.2491	-$0.87	$7.50 million	$0.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
CPHI China Pharma	N/A	N/A	N/A	N/A	N/A
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A
UTZ Utz Brands	$0.25	1.77%	+18.77%	N/A	3 Years

Latest CPHI, UTZ, INDP, and BCYC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/11/2026	UTZ Utz Brands	quarterly	$0.0630	3.69%	6/22/2026	6/22/2026	7/2/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	12.66	12.66
CPHI China Pharma	0.22	0.79	0.26
INDP Indaptus Therapeutics	N/A	2.34	2.34
UTZ Utz Brands	0.62	1.14	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
CPHI China Pharma	N/A
INDP Indaptus Therapeutics	7.06%
UTZ Utz Brands	95.97%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.00%
CPHI China Pharma	6.40%
INDP Indaptus Therapeutics	9.94%
UTZ Utz Brands	12.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	240	69.81 million	54.45 million	Optionable
CPHI China Pharma	250	40.52 million	15.92 million	Not Optionable
INDP Indaptus Therapeutics	6	113.24 million	101.99 million	Not Optionable
UTZ Utz Brands	3,300	143.89 million	125.57 million	Optionable

CPHI, UTZ, INDP, and BCYC Headlines

Recent News About These Companies

Systematic Financial Management LP Boosts Holdings in Utz Brands, Inc. $UTZ

July 25 at 5:27 AM | marketbeat.com

Utz Brands (NYSE:UTZ) Cut to Hold at DA Davidson

July 25 at 3:14 AM | americanbankingnews.com

Piper Sandler Reiterates "Neutral" Rating for Utz Brands (NYSE:UTZ)

July 25 at 2:30 AM | americanbankingnews.com

Utz Brands (NYSE:UTZ) Rating Lowered to "Sell" at Wall Street Zen

July 25 at 1:43 AM | americanbankingnews.com

Utz Brands (NYSE:UTZ) Cut to Sell at Wall Street Zen

July 25 at 1:41 AM | marketbeat.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Safety Insurance Group, Inc. (Nasdaq – SAFT), Utz Brands, Inc. (NYSE – UTZ), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN)

July 24 at 12:49 PM | globenewswire.com

Utz Brands (NYSE:UTZ) Cut to Hold at Piper Sandler

July 24 at 7:35 AM | marketbeat.com

$UTZ Notification: Utz Brands Investigated Over $14.25 per share Transaction – Current Shareholders Notified to Contact BFA Law

July 24 at 6:36 AM | globenewswire.com

KASKELA LAW ALERT: Does the Proposed $14.25 Per Share Buyout Price Shortchange Utz Brands (UTZ) Investors? Current UTZ Shareholders are Encouraged to Contact Kaskela Law to ...

July 24 at 1:02 AM | theglobeandmail.com

KASKELA LAW ALERT: Does the Proposed $14.25 Per Share Buyout Price Shortchange Utz Brands (UTZ) Investors? Current UTZ Shareholders are Encouraged to Contact Kaskela Law to Discuss Their Legal Rights and Options with Respect to the Buyout

July 23 at 2:50 PM | financialpost.comF

Utz Brands (NYSE:UTZ) Given Neutral Rating at Piper Sandler

July 23 at 9:59 AM | marketbeat.com

Utz Will Go Private in $2.9B Deal With Intersnack

July 23 at 9:00 AM | youtube.comY

Utz Brands (NYSE:UTZ) Stock Rating Lowered by DA Davidson

July 23 at 6:47 AM | marketbeat.com

Utz Brands, Inc. (NYSE:UTZ) Receives Consensus Recommendation of "Hold" from Analysts

July 23 at 4:28 AM | marketbeat.com

Barclays Downgrades Utz Brands (NYSE:UTZ) to Equal Weight

July 23 at 2:06 AM | americanbankingnews.com

Stephens Downgrades Utz Brands (NYSE:UTZ) to Equal Weight

July 23 at 2:06 AM | americanbankingnews.com

105-year-old salty snack maker sold in $2.9 billion deal

July 22 at 12:13 AM | mlive.comM

Baltimore favorite Utz plans to go private in deal valued at nearly $3B

July 22 at 7:13 PM | msn.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Utz Brands, Inc. (NYSE: UTZ)

July 22 at 4:00 PM | gurufocus.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Utz Brands, Inc. (NYSE: UTZ)

July 22 at 2:04 PM | prnewswire.com

Utz Brands (NYSE:UTZ) Sees Unusually-High Trading Volume - Should You Buy?

July 22 at 11:59 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI, UTZ, INDP, and BCYC Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$3.87 -0.29 (-6.97%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$3.88 +0.00 (+0.13%)

As of 07/24/2026 07:34 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

China Pharma NYSE:CPHI

$1.52 -0.33 (-17.84%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.38 -0.14 (-8.88%)

As of 07/24/2026 07:34 PM Eastern

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Indaptus Therapeutics NASDAQ:INDP

$2.61 -0.16 (-5.78%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$2.61 0.00 (0.00%)

As of 07/24/2026 07:34 PM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Utz Brands NYSE:UTZ

$14.10 +0.01 (+0.04%)

Closing price 07/24/2026 03:59 PM Eastern

Extended Trading

$14.09 -0.01 (-0.06%)

As of 07/24/2026 07:34 PM Eastern

Utz Brands, Inc. engages in manufacture, marketing, and distribution of snack foods. It offers a range of salty snacks, including salty snacks, including potato chips, tortilla chips, pretzels, cheese snacks, pork skins, veggie snacks, pub/party mixes, tortilla chips, salsa and dips, ready-to-eat popcorn, and other snacks under the Utz, Zapp's, ON THE BORDER, Golden Flake, Boulder Canyon, Hawaiian, TORTIYAHS!, etc. The company sells its products to wholesale and other distributors, grocery stores, convenience and drug stores, discount stores, mass merchandisers, membership club stores, hard discounters, and specialty and e-commerce retailers. Utz Brands, Inc. was founded in 1921 and is headquartered in Hanover, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CPHI, UTZ, INDP, and BCYC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CPHI, UTZ, INDP, and BCYC Earnings

Compare Dividends

Latest CPHI, UTZ, INDP, and BCYC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CPHI, UTZ, INDP, and BCYC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI, UTZ, INDP, and BCYC Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

China Pharma NYSE:CPHI

Indaptus Therapeutics NASDAQ:INDP

Utz Brands NYSE:UTZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CPHI, UTZ, INDP, and BCYC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CPHI, UTZ, INDP, and BCYC Earnings

Compare Dividends

Latest CPHI, UTZ, INDP, and BCYC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CPHI, UTZ, INDP, and BCYC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI, UTZ, INDP, and BCYC Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

China Pharma NYSE:CPHI

Indaptus Therapeutics NASDAQ:INDP

Utz Brands NYSE:UTZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools